US FDA approves AbbVie's drug for Parkinson's disease

ABBV•2026-09-25

The FDA approved AbbVie's tavapadon, branded Juvmo, for Parkinson's disease in adults. The once-a-day pill came through AbbVie's $8.7 billion acquisition of Cerevel Therapeutics in 2023.

US FDA approves AbbVie's drug for Parkinson's disease

1. FDA approval

2. Acquisition background

Related News

Repligen CEO Olivier Loeillot disposes of common shares worth $2,460,700

Monster Beverage CEO Americas Rob Gehring resigns, Emelie Tirre named interim Americas lead

Kura Oncology CSO Francis Burrows disposes of common shares worth $224,435.31

Catheter Precision board approves name change to Flyte Aviation

US longer-dated Treasury yields extend recent run-up after upbeat economic data